GEN Share Price

Open 0.45 Change Price %
High 0.45 1 Day 0.00 0.00
Low 0.43 1 Week 0.11 32.35
Close 0.45 1 Month -0.03 -6.25
Volume 211514 1 Year 0.41 1025.00
52 Week High 0.57
52 Week Low 0.01
GEN Important Levels
Resistance 2 0.47
Resistance 1 0.46
Pivot 0.44
Support 1 0.44
Support 2 0.43
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
ST 0.02 100.00%
ST 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TPL 0.02 100.00%
TPL 0.02 100.00%
QEC 0.74 42.31%
QEC 0.74 42.31%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
HE 0.04 -20.00%
HE 0.04 -20.00%
HBP 1.35 -12.90%
HBP 1.35 -12.90%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
CCM 0.08 -11.11%
CCM 0.08 -11.11%
More..

GeneNews Ltd. (TSE: GEN)

GEN Technical Analysis 4
As on 8th Dec 2016 GEN Share Price closed @ 0.45 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.21 & Buy for SHORT-TERM with Stoploss of 0.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
GEN Target for December
1st Target up-side 0.46
2nd Target up-side 0.53
3rd Target up-side 0.6
1st Target down-side 0.26
2nd Target down-side 0.19
3rd Target down-side 0.12
GEN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.genenews.com
GEN Address
GEN
445 Apple Creek Boulevard
Suite 220
Markham, ON L3R 9X7
Canada
Phone: 905-739-2030
Fax: 905-739-2031
Interactive Technical Analysis Chart GeneNews Ltd. ( GEN TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on GeneNews Ltd.
GEN Business Profile
GeneNews Limited, a molecular diagnostics company, focuses on the development and application of functional genomics to enable early diagnosis and personalized health management based on disease specific biomarkers. Its principal platform technology, the Sentinel Principle, detects and stages various diseases or medical conditions from a blood sample. The company is applying the Sentinel Principle in the areas of cancer, arthritis, cardiovascular diseases, and neurological disorders. Its lead product includes ColonSentry, a blood-based molecular test to aid physicians in determining an individual’s risk of having colorectal cancer. The company was formerly known as ChondroGene Limited and changed its name to GeneNews Limited in October 2006. GeneNews Limited was founded in 1998 and is headquartered in Markham, Canada.